[{"id":"ac4afb38-f9f0-4fe8-a6ec-8ae6a59cd318","acronym":"A041703","url":"https://clinicaltrials.gov/study/NCT03739814","created_at":"2021-01-18T18:19:08.468Z","updated_at":"2024-07-02T16:34:26.296Z","phase":"Phase 2","brief_title":"Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03739814 - A041703","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["ABL1 • BCR • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 05/08/2019","start_date":" 05/08/2019","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-06-13"},{"id":"6c3d7185-da62-4572-ad36-41e11a25a6bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05687032","created_at":"2023-01-17T14:59:23.664Z","updated_at":"2024-07-02T16:34:59.887Z","phase":"Phase 4","brief_title":"A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05687032","lead_sponsor":"Pfizer","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/24/2023","start_date":" 02/24/2023","primary_txt":" Primary completion: 08/07/2024","primary_completion_date":" 08/07/2024","study_txt":" Completion: 11/07/2025","study_completion_date":" 11/07/2025","last_update_posted":"2024-05-31"},{"id":"30181726-4a7a-4641-822a-3105dcd88382","acronym":"","url":"https://clinicaltrials.gov/study/NCT05303792","created_at":"2022-03-31T17:52:41.961Z","updated_at":"2024-07-02T16:35:01.827Z","phase":"Phase 2","brief_title":"Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT05303792","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD20 expression • CD22 positive","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/27/2023","start_date":" 02/27/2023","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2024-05-23"},{"id":"b927a829-cf0c-477b-9e90-8e3922097562","acronym":"","url":"https://clinicaltrials.gov/study/NCT03150693","created_at":"2021-01-18T15:31:43.755Z","updated_at":"2024-07-02T16:35:01.768Z","phase":"Phase 3","brief_title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03150693","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ABL1 • BCR • CD20 • CD22 • ITGB1","pipe":" | ","alterations":" CD20 positive • CD22 positive","tags":["ABL1 • BCR • CD20 • CD22 • ITGB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • cyclophosphamide intravenous"],"overall_status":"Suspended","enrollment":" Enrollment 310","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-05-23"},{"id":"77accf55-b1ad-4e14-aada-f3a5e55d16c9","acronym":"EU PIP Study","url":"https://clinicaltrials.gov/study/NCT05748171","created_at":"2023-02-28T13:01:32.364Z","updated_at":"2024-07-02T16:35:06.949Z","phase":"Phase 2","brief_title":"A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to ","source_id_and_acronym":"NCT05748171 - EU PIP Study","lead_sponsor":"Pfizer","biomarkers":" TP53 • KMT2A • CD22 • TCF3 • PBX1","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement • CD22 positive","tags":["TP53 • KMT2A • CD22 • TCF3 • PBX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/17/2023","start_date":" 05/17/2023","primary_txt":" Primary completion: 07/11/2028","primary_completion_date":" 07/11/2028","study_txt":" Completion: 07/09/2031","study_completion_date":" 07/09/2031","last_update_posted":"2024-04-30"},{"id":"5a81b871-3719-4334-984c-37ce472a34c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078306","created_at":"2023-10-11T16:12:45.179Z","updated_at":"2024-07-02T16:35:08.301Z","phase":"Phase 2","brief_title":"CD19CD22 CAR-T Therapy in Patients With High-Risk B Acute Lymphoblastic Leukemia (B-ALL).","source_id_and_acronym":"NCT06078306","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2024","start_date":" 04/20/2024","primary_txt":" Primary completion: 09/10/2024","primary_completion_date":" 09/10/2024","study_txt":" Completion: 09/10/2025","study_completion_date":" 09/10/2025","last_update_posted":"2024-04-22"},{"id":"0414e928-a316-42a5-8719-34e96c7da49c","acronym":"INO-FIRST","url":"https://clinicaltrials.gov/study/NCT06025682","created_at":"2023-09-06T14:09:39.551Z","updated_at":"2024-07-02T16:35:10.034Z","phase":"","brief_title":"Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INO","source_id_and_acronym":"NCT06025682 - INO-FIRST","lead_sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 158","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-04-11"},{"id":"d0063cdd-ab4b-4009-8105-73c4b7241cf5","acronym":"IRB-50836","url":"https://clinicaltrials.gov/study/NCT04088890","created_at":"2021-01-18T20:00:46.615Z","updated_at":"2024-07-02T16:35:15.877Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04088890 - IRB-50836","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2037","study_completion_date":" 12/30/2037","last_update_posted":"2024-03-07"},{"id":"3d90ab54-ff08-4d6e-8285-06ffa9b82ff3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03104491","created_at":"2021-01-18T15:17:48.325Z","updated_at":"2024-07-02T16:35:16.971Z","phase":"Phase 1/2","brief_title":"Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT03104491","lead_sponsor":"Leland Metheny","biomarkers":" BCL2 • BCL6 • CD22","pipe":" | ","alterations":" BCL6 rearrangement • CD22 positive • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • CD22 positive • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-02-29"},{"id":"b2fd0720-c684-4f4d-8475-75c34a4514c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04088864","created_at":"2021-01-18T20:00:46.042Z","updated_at":"2024-07-02T16:35:19.768Z","phase":"Phase 1","brief_title":"CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies","source_id_and_acronym":"NCT04088864","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 09/10/2036","study_completion_date":" 09/10/2036","last_update_posted":"2024-02-12"},{"id":"630b8e39-c4b6-44ab-bd82-dcc004446bd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04715217","created_at":"2021-02-17T11:57:45.039Z","updated_at":"2024-07-02T16:35:24.928Z","phase":"Phase 1/2","brief_title":"Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory B Cell Lymphoma","source_id_and_acronym":"NCT04715217","lead_sponsor":"Shanxi Province Cancer Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD19-CD22 CAR-T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/04/2021","start_date":" 01/04/2021","primary_txt":" Primary completion: 10/31/2024","primary_completion_date":" 10/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2023-12-29"},{"id":"c96af201-1fe0-41f1-9d48-5df4a19900bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919526","created_at":"2021-01-18T19:17:14.730Z","updated_at":"2024-07-02T16:35:26.713Z","phase":"Phase 1","brief_title":"Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor（CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL","source_id_and_acronym":"NCT03919526","lead_sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","biomarkers":" CD22","pipe":" | ","alterations":" CD19 positive • CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti-CD19/CD22 CAR-T cells"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 08/11/2019","start_date":" 08/11/2019","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2023-12-08"},{"id":"47a91841-a46b-498c-8a05-c78c3450d849","acronym":"","url":"https://clinicaltrials.gov/study/NCT03677596","created_at":"2021-01-18T18:02:08.633Z","updated_at":"2024-07-02T16:35:28.361Z","phase":"Phase 4","brief_title":"A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients","source_id_and_acronym":"NCT03677596","lead_sponsor":"Pfizer","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 102","initiation":"Initiation: 07/01/2019","start_date":" 07/01/2019","primary_txt":" Primary completion: 09/21/2022","primary_completion_date":" 09/21/2022","study_txt":" Completion: 05/26/2023","study_completion_date":" 05/26/2023","last_update_posted":"2023-11-22"},{"id":"c900f528-6d73-42da-b291-b7727c78afb7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06081478","created_at":"2023-10-14T01:13:05.024Z","updated_at":"2024-07-02T16:35:33.535Z","phase":"Phase 2","brief_title":"CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT06081478","lead_sponsor":"Beijing Tongren Hospital","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/18/2022","start_date":" 01/18/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-13"},{"id":"df56bed1-a43b-40d3-baea-ecf1d6a1b137","acronym":"ALL 001","url":"https://clinicaltrials.gov/study/NCT03962465","created_at":"2021-01-18T19:29:49.915Z","updated_at":"2024-07-02T16:35:39.386Z","phase":"Phase 1","brief_title":"Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL","source_id_and_acronym":"NCT03962465 - ALL 001","lead_sponsor":"University of Virginia","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • Oncaspar liquid (pegaspargase)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/22/2022","start_date":" 07/22/2022","primary_txt":" Primary completion: 07/15/2023","primary_completion_date":" 07/15/2023","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-08-22"},{"id":"d478b0d6-30dd-47cf-b944-82d63c993fca","acronym":"","url":"https://clinicaltrials.gov/study/NCT04029038","created_at":"2021-01-18T19:46:36.486Z","updated_at":"2024-07-02T16:35:39.488Z","phase":"Phase 1/2","brief_title":"Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma","source_id_and_acronym":"NCT04029038","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/15/2019","start_date":" 05/15/2019","primary_txt":" Primary completion: 11/16/2022","primary_completion_date":" 11/16/2022","study_txt":" Completion: 11/16/2022","study_completion_date":" 11/16/2022","last_update_posted":"2023-08-21"},{"id":"ec3e743e-1b1e-4a2e-a3aa-858146aacd86","acronym":"","url":"https://clinicaltrials.gov/study/NCT05597085","created_at":"2022-10-27T15:58:40.495Z","updated_at":"2024-07-02T16:35:40.578Z","phase":"","brief_title":"A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment","source_id_and_acronym":"NCT05597085","lead_sponsor":"Pfizer","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Besponsa (inotuzumab ozogamicin)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 03/08/2023","start_date":" 03/08/2023","primary_txt":" Primary completion: 07/04/2023","primary_completion_date":" 07/04/2023","study_txt":" Completion: 07/04/2023","study_completion_date":" 07/04/2023","last_update_posted":"2023-08-08"},{"id":"67a1b566-5352-4456-a3e7-7e3b946bf5d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04340154","created_at":"2021-01-18T21:00:26.726Z","updated_at":"2024-07-02T16:35:41.174Z","phase":"Phase 2","brief_title":"Study of Sequential CAR-T Cell Treating Leukemia Children","source_id_and_acronym":"NCT04340154","lead_sponsor":"Beijing Boren Hospital","biomarkers":" ABL1 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 positive • CD22 expression","tags":["ABL1 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/01/2020","start_date":" 05/01/2020","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2023-08-02"},{"id":"527397ee-a21a-4630-81bf-27f9c9bfe907","acronym":"","url":"https://clinicaltrials.gov/study/NCT05016947","created_at":"2021-08-23T12:53:04.157Z","updated_at":"2024-07-02T16:35:42.681Z","phase":"Phase 1","brief_title":"Venetoclax Plus Inotuzumab for B-ALL","source_id_and_acronym":"NCT05016947","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/24/2021","start_date":" 09/24/2021","primary_txt":" Primary completion: 07/23/2024","primary_completion_date":" 07/23/2024","study_txt":" Completion: 06/23/2026","study_completion_date":" 06/23/2026","last_update_posted":"2023-07-18"},{"id":"bb237587-56bb-4728-a5f6-2bd9743a439d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03991884","created_at":"2021-01-18T19:37:32.714Z","updated_at":"2024-07-02T16:35:43.756Z","phase":"Phase 1","brief_title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03991884","lead_sponsor":"University of Washington","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • daunorubicin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/24/2019","start_date":" 09/24/2019","primary_txt":" Primary completion: 10/20/2022","primary_completion_date":" 10/20/2022","study_txt":" Completion: 06/28/2023","study_completion_date":" 06/28/2023","last_update_posted":"2023-07-06"},{"id":"df7f24f6-9030-42d5-a30b-4cd3d8227f11","acronym":"","url":"https://clinicaltrials.gov/study/NCT01925131","created_at":"2021-01-29T07:05:14.388Z","updated_at":"2024-07-02T16:35:49.087Z","phase":"Phase 1","brief_title":"S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia","source_id_and_acronym":"NCT01925131","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" CD22 • CD4","pipe":" | ","alterations":" CD22 positive","tags":["CD22 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 06/13/2014","start_date":" 06/13/2014","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-05-03"},{"id":"074dadc5-1353-4b92-b222-659e5cb7d757","acronym":"","url":"https://clinicaltrials.gov/study/NCT04648475","created_at":"2021-01-19T20:40:05.443Z","updated_at":"2024-07-02T16:35:50.308Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT04648475","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD22 • IL10","pipe":" | ","alterations":" CD19 expression • CD22 positive • CD22 expression • IL10 elevation","tags":["IL6 • CD22 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 positive • CD22 expression • IL10 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/25/2020","start_date":" 08/25/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"40a4dc8e-3973-4154-83e4-34a921b399c5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04649983","created_at":"2021-01-19T20:40:33.018Z","updated_at":"2024-07-02T16:35:50.276Z","phase":"Phase 1/2","brief_title":"CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT04649983","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD22","pipe":" | ","alterations":" CD19 expression • CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 positive • CD22 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"6067170a-b400-4596-b990-2bd8229909eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04782193","created_at":"2021-03-04T12:52:22.373Z","updated_at":"2024-07-02T16:35:50.281Z","phase":"Phase 1/2","brief_title":"a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma","source_id_and_acronym":"NCT04782193","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD22 • IL10","pipe":" | ","alterations":" CD19 expression • CD22 positive • CD22 expression • IL10 elevation","tags":["IL6 • CD22 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 positive • CD22 expression • IL10 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 and CD22 targeted prime CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/23/2021","start_date":" 05/23/2021","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"}]